161 related articles for article (PubMed ID: 33151472)
21. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.
Hutchinson KE; Lipson D; Stephens PJ; Otto G; Lehmann BD; Lyle PL; Vnencak-Jones CL; Ross JS; Pietenpol JA; Sosman JA; Puzanov I; Miller VA; Pao W
Clin Cancer Res; 2013 Dec; 19(24):6696-702. PubMed ID: 24345920
[TBL] [Abstract][Full Text] [Related]
22. Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system.
van de Nes J; Gessi M; Sucker A; Möller I; Stiller M; Horn S; Scholz SL; Pischler C; Stadtler N; Schilling B; Zimmer L; Hillen U; Scolyer RA; Buckland ME; Lauriola L; Pietsch T; Waha A; Schadendorf D; Murali R; Griewank KG
J Neurooncol; 2016 May; 127(3):435-44. PubMed ID: 26744134
[TBL] [Abstract][Full Text] [Related]
23. Next-Generation Sequencing Reveals Pathway Activations and New Routes to Targeted Therapies in Cutaneous Metastatic Melanoma.
Carlson JA; Caldeira Xavier JC; Tarasen A; Sheehan CE; Otto G; Miller VA; Stephens PJ; Elvin JA; Vergilio JA; Suh J; Gay LM; Ross JS
Am J Dermatopathol; 2017 Jan; 39(1):1-13. PubMed ID: 28045747
[TBL] [Abstract][Full Text] [Related]
24. Copy number changes of clinically actionable genes in melanoma, non-small cell lung cancer and colorectal cancer-A survey across 822 routine diagnostic cases.
Pfarr N; Penzel R; Klauschen F; Heim D; Brandt R; Kazdal D; Jesinghaus M; Herpel E; Schirmacher P; Warth A; Weichert W; Endris V; Stenzinger A
Genes Chromosomes Cancer; 2016 Nov; 55(11):821-33. PubMed ID: 27218826
[TBL] [Abstract][Full Text] [Related]
25. High-throughput detection of clinically targetable alterations using next-generation sequencing.
Vendrell JA; Grand D; Rouquette I; Costes V; Icher S; Selves J; Larrieux M; Barbe A; Brousset P; Solassol J
Oncotarget; 2017 Jun; 8(25):40345-40358. PubMed ID: 28404952
[TBL] [Abstract][Full Text] [Related]
26. A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance.
Xia J; Jia P; Hutchinson KE; Dahlman KB; Johnson D; Sosman J; Pao W; Zhao Z
Mol Cancer Ther; 2014 Jul; 13(7):1918-28. PubMed ID: 24755198
[TBL] [Abstract][Full Text] [Related]
27. Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies.
Fisher KE; Zhang L; Wang J; Smith GH; Newman S; Schneider TM; Pillai RN; Kudchadkar RR; Owonikoko TK; Ramalingam SS; Lawson DH; Delman KA; El-Rayes BF; Wilson MM; Sullivan HC; Morrison AS; Balci S; Adsay NV; Gal AA; Sica GL; Saxe DF; Mann KP; Hill CE; Khuri FR; Rossi MR
J Mol Diagn; 2016 Mar; 18(2):299-315. PubMed ID: 26801070
[TBL] [Abstract][Full Text] [Related]
28. Use of clinical next-generation sequencing to identify melanomas harboring SMARCB1 mutations.
Stockman DL; Curry JL; Torres-Cabala CA; Watson IR; Siroy AE; Bassett RL; Zou L; Patel KP; Luthra R; Davies MA; Wargo JA; Routbort MA; Broaddus RR; Prieto VG; Lazar AJ; Tetzlaff MT
J Cutan Pathol; 2015 May; 42(5):308-17. PubMed ID: 25754356
[TBL] [Abstract][Full Text] [Related]
29. Meta-Analysis and Systematic Review of the Genomics of Mucosal Melanoma.
Broit N; Johansson PA; Rodgers CB; Walpole ST; Newell F; Hayward NK; Pritchard AL
Mol Cancer Res; 2021 Jun; 19(6):991-1004. PubMed ID: 33707307
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material.
Steeghs EMP; Kroeze LI; Tops BBJ; van Kempen LC; Ter Elst A; Kastner-van Raaij AWM; Hendriks-Cornelissen SJB; Hermsen MJW; Jansen EAM; Nederlof PM; Schuuring E; Ligtenberg MJL; Eijkelenboom A
BMC Cancer; 2020 Apr; 20(1):291. PubMed ID: 32264863
[TBL] [Abstract][Full Text] [Related]
31. Assessing the Diagnostic Yield of Targeted Next-Generation Sequencing for Melanoma and Gastrointestinal Tumors.
Garg S; Grenier S; Misyura M; Sukhai MA; Thomas M; Kamel-Reid S; Stockley T
J Mol Diagn; 2020 Apr; 22(4):467-475. PubMed ID: 32036084
[TBL] [Abstract][Full Text] [Related]
32. A high-throughput panel for identifying clinically relevant mutation profiles in melanoma.
Dutton-Regester K; Irwin D; Hunt P; Aoude LG; Tembe V; Pupo GM; Lanagan C; Carter CD; O'Connor L; O'Rourke M; Scolyer RA; Mann GJ; Schmidt CW; Herington A; Hayward NK
Mol Cancer Ther; 2012 Apr; 11(4):888-97. PubMed ID: 22383533
[TBL] [Abstract][Full Text] [Related]
33. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive clinicopathological and molecular analysis of primary malignant melanoma of the oesophagus.
Tsuyama S; Kohsaka S; Hayashi T; Suehara Y; Hashimoto T; Kajiyama Y; Tsurumaru M; Ueno T; Mano H; Yao T; Saito T
Histopathology; 2021 Jan; 78(2):240-251. PubMed ID: 32654197
[TBL] [Abstract][Full Text] [Related]
35. Prospective Clinical Integration of an Amplicon-Based Next-Generation Sequencing Method to Select Advanced Non-Small-Cell Lung Cancer Patients for Genotype-Tailored Treatments.
Zugazagoitia J; Rueda D; Carrizo N; Enguita AB; Gómez-Sánchez D; Díaz-Serrano A; Jiménez E; Mérida A; Calero R; Lujan R; De Miguel E; Gámez P; Díaz-Hellín V; Nuñez JA; Iglesias L; Ferrer I; Paz-Ares L; Ponce-Aix S
Clin Lung Cancer; 2018 Jan; 19(1):65-73.e7. PubMed ID: 28780976
[TBL] [Abstract][Full Text] [Related]
36. Validation of an NGS mutation detection panel for melanoma.
Reiman A; Kikuchi H; Scocchia D; Smith P; Tsang YW; Snead D; Cree IA
BMC Cancer; 2017 Feb; 17(1):150. PubMed ID: 28228113
[TBL] [Abstract][Full Text] [Related]
37. Intragenic NF1 deletions in sinonasal mucosal malignant melanoma.
Riobello C; Casanueva Muruais R; Suárez-Fernández L; García-Marín R; Cabal VN; Blanco-Lorenzo V; Franchi A; Laco J; López F; Llorente JL; Hermsen MA
Pigment Cell Melanoma Res; 2022 Jan; 35(1):88-96. PubMed ID: 34547192
[TBL] [Abstract][Full Text] [Related]
38. Landscape of RAS Variations in 17,993 Pan-cancer Patients Identified by Next-generation Sequencing.
Zhou S; Zhang D; Li J; Zhao J; Wang G; Zhang Y; Bai Y; Chen D; Wu H
Pathol Oncol Res; 2020 Oct; 26(4):2835-2837. PubMed ID: 32602003
[TBL] [Abstract][Full Text] [Related]
39. Genetic profiling of melanoma in routine diagnostics: assay performance and molecular characteristics in a consecutive series of 274 cases.
Leichsenring J; Stögbauer F; Volckmar AL; Buchhalter I; Oliveira C; Kirchner M; Fröhling S; Hassel J; Enk A; Schirmacher P; Endris V; Penzel R; Stenzinger A
Pathology; 2018 Dec; 50(7):703-710. PubMed ID: 30348504
[TBL] [Abstract][Full Text] [Related]
40. Ion Torrent next-generation sequencing for routine identification of clinically relevant mutations in colorectal cancer patients.
Malapelle U; Vigliar E; Sgariglia R; Bellevicine C; Colarossi L; Vitale D; Pallante P; Troncone G
J Clin Pathol; 2015 Jan; 68(1):64-8. PubMed ID: 25378536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]